Enzalutamide (MDV3100) 化学構造
分子量: 464.44



Quality Control & MSDS


  • Compare Androgen Receptor Inhibitors
    Androgen Receptor製品生物活性の比較
  • 研究分野



製品説明 Enzalutamide (MDV3100)は、36nMのIC50をもつアンドロゲン受容体(AR)敵対者です。
ターゲット Androgen-receptor
IC50 36 nM [1]
In vitro試験 Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide could inhibit the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys). [1] Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
human LNCAP MnroR5l1d3SxeHnjJGF{e2G7 NVr3NG06PyCmYYnz MX[5OUUhTXSRSB?= MVzJR|UxRTVwMUKg{txO
human LNCAP MnzsSpVv[3Srb36gRZN{[Xl? MnTuNUDPxE1? NWL4VXgzTE2VTx?= MVfJcohq[mm2czDwdo9{fGG2ZTDzdIVkcW[rYzDhcpRq\2WwIIPlZ5JmfGmxbjDpckBpfW2jbjDMUmNCWCClZXzsd{BmgHC{ZYPzbY5oKGGwZILv[4VvKHKnY3XweI9zKGG2IEGwNE0yODBybl2=
VCaP NVXvUlI5TnWwY4Tpc44hSXO|YYm= NVPkRVVEOTBizszN M{S2[VI1KGh? M2fvfGROW09? NVv1[XZtW3WycILld5NmeyCuaXfhcoQudWWmaXH0[YQhSVJvRlygd4lodmGuaX7nJC=>
BCK4 MmH5SpVv[3Srb36gRZN{[Xl? NFPhVY8yOCEQvF2= MnPwO{Bl[Xm| MWfEUXNQ Mm[1TY5pcWKrdIOg[ZN1emGmaX;sMY1m\GmjdHXkJJBzd2yrZnXyZZRqd25?
MCF7s M12yO2Z2dmO2aX;uJGF{e2G7 NF\rcYoyOCEQvF2= MkLTOkBl[Xm| NIT2O4hFVVOR M{fYW2lvcGmkaYTzJIV{fHKjZHnvcE1u\WSrYYTl[EBxem:uaX\ldoF1cW:w
PC-3 M4L5UWZ2dmO2aX;uJGF{e2G7 NEfROVkyOCEQvF2= MmDUO|IhcA>? MoPCSG1UVw>? M3LHeGRw\XNibn;0JIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;u
CWR22Rv1 M4jhdWZ2dmO2aX;uJGF{e2G7 NVnkbYtOOTVizszN NFu5Vo0zPCCq MmHxSG1UVw>? NFWzTXBFd2W|IH7veEBi\m[nY4SgeIhmKG[3bHygcIVv\3SqIFHSJIV5eHKnc4Ppc44>

... Click to View More Cell Line Experimental Data

In vivo試験 Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg. [1]
臨床試験 Enzalutamide is currently in Phase III clinical trial in progressive metastatic prostate cancer.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

AR reporter assay Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed.

細胞アッセイ: [1]

細胞株 LNCaP or LNCaP/AR cells
濃度 0-10 μM
反応時間 1-4 days
実験の流れ Enzalutamide is diluted in DMSO. LNCaP or LNCaP/AR cells (104 cells/well) are androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells are challenged with various concentrations of Enzalutamide in media containing 5-10% charcoal-stripped serum.

動物実験: [1]

動物モデル Castration-resistant LNCaP/HR xenografts in male SCID mice
製剤 Formulated in 1% carboxymethyl cellulose, 0.1% Tween-80, 5% DMSO
投薬量 10 mg/kg
投与方法 Administered via gavage daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Enzalutamide (MDV3100) SDF
分子量 464.44


CAS No. 915087-33-1
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 92 mg/mL warmed (198.08 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 2% DMSO/30% PEG300 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名  4-​[3-​[4-​cyano-​3-​(trifluoromethyl)​phenyl]​-​5,​5-​dimethyl-​4-​oxo-​2-​thioxo-​1-​imidazolidinyl]​-​2-​fluoro-​N-​methyl-benzamide

カスタマーフィードバック (3)

Click to enlarge
Source Cancer Sci, 2013, 104(8), 1027-32. Enzalutamide (MDV3100) purchased from Selleck
Method Transfection and luciferase activity assay
Cell Lines Tramp-C1, PTENCaP8 cells
Incubation Time 48 h
Results When bicalutamide and MDV3100were used to block AR, BMP-6 no longer increased the probasin promoter activity in Tramp-C1 and PTENCaP8 whenRAW 264.7 cells were present.

Click to enlarge
Source PLoS One, 2013, 8, e53701. Enzalutamide (MDV3100) purchased from Selleck
Method Western blots/qPCR
Cell Lines CWR-R1 cells
Concentrations 10 μM
Incubation Time 48 h
Results MDV3100 treatment reverses androgen-mediated decreases of Sox2 protein and mRNA in CWR-R1 cells 48 hours after a 24 hour pretreatment with R1881.

Click to enlarge
Source PLoS One, 2013, 8, e53701. Enzalutamide (MDV3100) purchased from Selleck
Method qPCR
Cell Lines prostate cancer cell lines
Concentrations 10 μM
Incubation Time 30 d
Results There is a significant decrease in PSA expression under continuous AR inhibition with MDV3100.

文献中の引用 (17)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related アンドロゲン受容体 化学物質

  • LCZ696

    LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

  • Endoxifen HCl

    Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.

  • Licochalcone A

    Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.

  • Bicalutamide


  • ARN-509

    ARN-509 is a selective androgen receptor inhibitor with IC50 of 16 nM.

  • Galeterone

    Galeteroneは、選択的なCYP17阻害剤とアンドロゲン受容体(AR)敵対者で、IC50 がそれぞれ 300 nM と 384 nMです。

  • Andarine


  • Dehydroepiandrosterone (DHEA)

    Dehydroepiandrosterone(DHEA) is a 19-carbon endogenous natural steroid hormone.

  • Cyproterone Acetate

    Cyproterone acetate は、7.1nMのIC50をもつアンドロゲン受容体(AR)敵対者です。


Tags: Enzalutamide (MDV3100)を買う | Enzalutamide (MDV3100)供給者 | Enzalutamide (MDV3100)を購入する | Enzalutamide (MDV3100)費用 | Enzalutamide (MDV3100)生産者 | オーダーEnzalutamide (MDV3100) | Enzalutamide (MDV3100)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description